The DOI matches its Crossref record; 157 of the 157 references it cites were found in a registry or an index.
Nonalcoholic Fatty Liver Disease: From Steatosis to Cirrhosis
Abstract
Nonalcoholic steatohepatitis (NASH), the lynchpin between steatosis and cirrhosis in the spectrum of nonalcoholic fatty liver disorders (NAFLD), was barely recognized in 1981. NAFLD is now present in 17% to 33% of Americans, has a worldwide distribution, and parallels the frequency of central adiposity, obesity, insulin resistance, metabolic syndrome and type 2 diabetes. NASH could be present in one third of NAFLD cases. Age, activity of steatohepatitis, and established fibrosis predispose to cirrhosis, which has a 7- to 10-year liver-related mortality of 12% to 25%. Many cases of cryptogenic cirrhosis are likely endstage NASH. While endstage NAFLD currently accounts for 4% to 10% of liver transplants, this may soon rise. Pathogenic concepts for NAFLD/NASH must account for the strong links with overnutrition and underactivity, insulin resistance, and genetic factors. Lipotoxicity, oxidative stress, cytokines, and other proinflammatory mediators may each play a role in transition of steatosis to NASH. The present “gold standard” management of NASH is modest weight reduction, particularly correction of central obesity achieved by combining dietary measures with increased physical activity. Whether achieved by “lifestyle adjustment” or anti-obesity surgery, this improves insulin resistance and reverses steatosis, hepatocellular injury, inflammation, and fibrosis. The same potential for “unwinding” fibrotic NASH is indicated by studies of the peroxisome proliferation activator receptor (PPAR)- γ agonist “glitazones,” but these agents may improve liver disease at the expense of worsening obesity. Future challenges are to approach NAFLD as a preventive public health initiative and to motivate affected persons to adopt a healthier lifestyle. (Hepatology 2006;43:S99-S112.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Nonalcoholic Fatty Liver Disease
Angulo, P. (2002) · New England Journal of Medicine · doi:10.1056/nejmra011775 · Cited by 5,228
Steatohepatitis: A tale of two “hits”?
Day, C. P., & James, O. F. W. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70599-2 · Cited by 4,285
Nonalcoholic Steatohepatitis: A Proposal for Grading and Staging The Histological Lesions
Brunt, E. M., Janney, C. G., Di Bisceglie, A. M., Neuschwander-Tetri, B. A., & Bacon, B. R. (1999) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1999.01377.x · Cited by 3,907
Prevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of Ethnicity
Browning, J. D., Szczepaniak, L. S., Dobbins, R., Nuremberg, P., Horton, J. D., Cohen, J. C., Grundy, S. M., & Hobbs, H. H. (2004) · Hepatology · doi:10.1002/hep.20466 · Cited by 3,664
Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604
Cited by
Items 101–160 of 160
High fat diet induces dysregulation of hepatic oxygen gradients and mitochondrial function in vivo
Mantena, S. K., Vaughn, D. P., Andringa, K. K., Eccleston, H. B., King, A. L., Abrams, G. A., Doeller, J. E., Kraus, D. W., Darley-Usmar, V. M., & Bailey, S. M. (2009) · Biochemical Journal · doi:10.1042/bj20080868 · Cited by 265
Velayudham, A., Dolganiuc, A., Ellis, M., Petrasek, J., Kodys, K., Mandrekar, P., & Szabo, G. (2009) · Hepatology · doi:10.1002/hep.22711 · Cited by 263
Pawlik, T. M., Olino, K., Gleisner, A. L., Torbenson, M., Schulick, R., & Choti, M. A. (2007) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-007-0149-4 · Cited by 263
Loss of Nrf2 markedly exacerbates nonalcoholic steatohepatitis
Chowdhry, S., Nazmy, M. H., Meakin, P. J., Dinkova-Kostova, A. T., Walsh, S. V., Tsujita, T., Dillon, J. F., Ashford, M. L. J., & Hayes, J. D. (2010) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2009.11.007 · Cited by 261
Ni, Y., Nagashimada, M., Zhuge, F., Zhan, L., Nagata, N., Tsutsui, A., Nakanuma, Y., Kaneko, S., & Ota, T. (2015) · Scientific Reports · doi:10.1038/srep17192 · Cited by 261
Foster, T., Budoff, M. J., Saab, S., Ahmadi, N., Gordon, C., & Guerci, A. D. (2011) · American Journal of Gastroenterology · doi:10.1038/ajg.2010.299 · Cited by 260
Aron-Wisnewsky, J., Minville, C., Tordjman, J., Lévy, P., Bouillot, J.-L., Basdevant, A., Bedossa, P., Clément, K., & Pépin, J.-L. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.04.022 · Cited by 255
Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis
Adorini, L., Pruzanski, M., & Shapiro, D. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.05.012 · Cited by 259
Treatment options for alcoholic and non-alcoholic fatty liver disease: A review
Singh, S., Osna, N. A., & Kharbanda, K. K. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i36.6549 · Cited by 257
A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease
Fernández-Miranda, C., Pérez-Carreras, M., Colina, F., López-Alonso, G., Vargas, C., & Solís-Herruzo, J. A. (2008) · Digestive and Liver Disease · doi:10.1016/j.dld.2007.10.002 · Cited by 256
Chen, Y., Wang, X., Wang, J., Yan, Z., & Luo, J. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.02.063 · Cited by 248
Highly Purified Eicosapentaenoic Acid Treatment Improves Nonalcoholic Steatohepatitis
Tanaka, N., Sano, K., Horiuchi, A., Tanaka, E., Kiyosawa, K., & Aoyama, T. (2008) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e31815591aa · Cited by 248
Oxidative stress promotes pathologic polyploidization in nonalcoholic fatty liver disease
Gentric, G., Maillet, V., Paradis, V., Couton, D., L’Hermitte, A., Panasyuk, G., Fromenty, B., Celton-Morizur, S., & Desdouets, C. (2015) · Journal of Clinical Investigation · doi:10.1172/jci73957 · Cited by 240
Cannito, S., Novo, E., di Bonzo, L. V., Busletta, C., Colombatto, S., & Parola, M. (2010) · Antioxidants & Redox Signaling · doi:10.1089/ars.2009.2737 · Cited by 239
Microbiome-derived ethanol in nonalcoholic fatty liver disease
Meijnikman, A. S., Davids, M., Herrema, H., Aydin, O., Tremaroli, V., Rios-Morales, M., Levels, H., Bruin, S., de Brauw, M., Verheij, J., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02016-6 · Cited by 215
Thyroid function and the risk of nonalcoholic fatty liver disease: the Rotterdam study
Bano, A., Chaker, L., Plompen, E. P. C., Hofman, A., Dehghan, A., Franco, O. H., Janssen, H. L. A., Murad, S. D., & Peeters, R. P. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-1300 · Cited by 209
Abnormal Hepatic Energy Homeostasis in Type 2 Diabetes†
Szendroedi, J., Chmelik, M., Schmid, A. I., Nowotny, P., Brehm, A., Krssak, M., Moser, E., & Roden, M. (2009) · Hepatology · doi:10.1002/hep.23093 · Cited by 204
Body mass index and risk of liver cirrhosis in middle aged UK women: prospective study
Liu, B., Balkwill, A., Reeves, G., Beral, V., & Collaborators., O. B. O. T. M. W. S. (2010) · BMJ · doi:10.1136/bmj.c912 · Cited by 202
Kotronen, A., Juurinen, L., Hakkarainen, A., Westerbacka, J., Cornér, A., Bergholm, R., & Yki-Järvinen, H. (2008) · Diabetes Care · doi:10.2337/dc07-1463 · Cited by 196
Abdelmalek, M. F., Lazo, M., Horska, A., Bonekamp, S., Lipkin, E. W., Balasubramanyam, A., Bantle, J. P., Johnson, R. J., Diehl, A. M., & Clark, J. M. (2012) · Hepatology · doi:10.1002/hep.25741 · Cited by 190
“, steatohepatitis, hepatic fibrosis, or cirrhosis).(1) The rapid rise in NAFLD supports the role for environmental factors, which, in tandem with predisposing genetic factors, likely contribute to the pathogenesis and epidemic of NAFLD.”
BackgroundRosenberg, P., Urwitz, H., Johannesson, A., Ros, A.-M., Lindholm, J., Kinnman, N., & Hultcrantz, R. (2007) · Journal of Hepatology · doi:10.1016/j.jhep.2007.01.024 · Cited by 185
Chehrehgosha, H., Sohrabi, M. R., Ismail-Beigi, F., Malek, M., Reza Babaei, M., Zamani, F., Ajdarkosh, H., Khoonsari, M., Fallah, A. E., & Khamseh, M. E. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01011-3 · Cited by 173
Resveratrol improves hepatic steatosis by inducing autophagy through the cAMP signaling pathway
Zhang, Y., Chen, M., Zhou, Y., Yi, L., Gao, Y., Ran, L., Chen, S., Zhang, T., Zhou, X., Zou, D., et al. (2015) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201500016 · Cited by 170
Mirza, M. S. (2011) · ISRN Gastroenterology · doi:10.5402/2011/592404 · Cited by 148
Omega-3 polyunsaturated fatty acids as a treatment strategy for nonalcoholic fatty liver disease
Jump, D. B., Lytle, K. A., Depner, C. M., & Tripathy, S. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.07.007 · Cited by 142
Pawlak, M., Baugé, E., Bourguet, W., De Bosscher, K., Lalloyer, F., Tailleux, A., Lebherz, C., Lefebvre, P., & Staels, B. (2014) · Hepatology · doi:10.1002/hep.27297 · Cited by 141
Gan, L., Chitturi, S., & Farrell, G. C. (2011) · Current Gerontology and Geriatrics Research · doi:10.1155/2011/831536 · Cited by 135
Self-citationVallin, M., Guillaud, O., Boillot, O., Hervieu, V., Scoazec, J.-Y., & Dumortier, J. (2014) · Liver Transplantation · doi:10.1002/lt.23936 · Cited by 137
Understanding bile acid signaling in diabetes: From pathophysiology to therapeutic targets
Ferrell, J. M., & Chiang, J. Y. L. (2019) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2019.0043 · Cited by 139
Hajifathalian, K., Torabi Sagvand, B., & McCullough, A. J. (2019) · Hepatology · doi:10.1002/hep.30226 · Cited by 128
Saponaro, F., Sestito, S., Runfola, M., Rapposelli, S., & Chiellini, G. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00331 · Cited by 124
Luo, X.-Y., Takahara, T., Kawai, K., Fujino, M., Sugiyama, T., Tsuneyama, K., Tsukada, K., Nakae, S., Zhong, L., & Li, X.-K. (2013) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00193.2013 · Cited by 120
Yari, Z., Rahimlou, M., Eslamparast, T., Ebrahimi-Daryani, N., Poustchi, H., & Hekmatdoost, A. (2016) · International Journal of Food Sciences and Nutrition · doi:10.3109/09637486.2016.1161011 · Cited by 118
Modulation of glucose metabolism by the renin-angiotensin-aldosterone system
Favre, G. A., Esnault, V. L. M., & Van Obberghen, E. (2015) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00391.2014 · Cited by 114
Modeling human nonalcoholic fatty liver disease (NAFLD) with an organoids-on-a-chip system
Wang, Y., Wang, H., Deng, P., Tao, T., Liu, H., Wu, S., Chen, W., & Qin, J. (2020) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.0c00682 · Cited by 109
Rector, R. S., Thyfault, J. P., Laye, M. J., Morris, R. T., Borengasser, S. J., Uptergrove, G. M., Chakravarthy, M. V., Booth, F. W., & Ibdah, J. A. (2008) · The Journal of Physiology · doi:10.1113/jphysiol.2008.156745 · Cited by 110
Kelly, D. M., Nettleship, J. E., Akhtar, S., Muraleedharan, V., Sellers, D. J., Brooke, J. C., McLaren, D. S., Channer, K. S., & Jones, T. H. (2014) · Life Sciences · doi:10.1016/j.lfs.2014.06.007 · Cited by 98
Lipotoxicity in HepG2 cells triggered by free fatty acids.
(2011) · PubMed Central · Cited by 94
Li, Q., Li, L., Wang, F., Chen, J., Zhao, Y., Wang, P., Nilius, B., Liu, D., & Zhu, Z. (2013) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-013-1274-4 · Cited by 91
Larter, C. Z., Yeh, M. M., Van Rooyen, D. M., Brooling, J., Ghatora, K., & Farrell, G. C. (2012) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2011.06939.x · Cited by 89
Self-citationNakayama, H., Otabe, S., Ueno, T., Hirota, N., Yuan, X., Fukutani, T., Hashinaga, T., Wada, N., & Yamada, K. (2007) · Metabolism · doi:10.1016/j.metabol.2006.11.004 · Cited by 79
Tanaka, N., Zhang, X., Sugiyama, E., Kono, H., Horiuchi, A., Nakajima, T., Kanbe, H., Tanaka, E., Gonzalez, F. J., & Aoyama, T. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.07.031 · Cited by 78
Osteocalcin protects against nonalcoholic steatohepatitis in a mouse model of metabolic syndrome
Gupte, A. A., Sabek, O. M., Fraga, D., Minze, L. J., Nishimoto, S. K., Liu, J. Z., Afshar, S., Gaber, L., Lyon, C. J., Gaber, A. O., et al. (2014) · Endocrinology · doi:10.1210/en.2014-1430 · Cited by 70
Saeed, N., Nadeau, B., Shannon, C., & Tincopa, M. (2019) · Nutrients · doi:10.3390/nu11123064 · Cited by 65
PTP1B inhibitor improves both insulin resistance and lipid abnormalities in vivo and in vitro
Ma, Y.-M., Tao, R.-Y., Liu, Q., Li, J., Tian, J.-Y., Zhang, X.-L., Xiao, Z.-Y., & Ye, F. (2011) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-011-0876-4 · Cited by 62
Lê, K.-A., & Bortolotti, M. (2008) · Current Opinion in Clinical Nutrition and Metabolic Care · doi:10.1097/mco.0b013e328302f3ec · Cited by 60
Kechagias, S., Zanjani, S., Gjellan, S., Leinhard, O. D., Kihlberg, J., Smedby, Ö., Johansson, L., Kullberg, J., Ahlström, H., Lindström, T., et al. (2011) · Annals of Medicine · doi:10.3109/07853890.2011.588246 · Cited by 57
Insulin-Like Growth Factor-1 Deficiency and Cirrhosis Establishment
de la Garza, R. G., Morales-Garza, L. A., Martin-Estal, I., & Castilla-Cortazar, I. (2017) · Journal of Clinical Medicine Research · doi:10.14740/jocmr2761w · Cited by 55
Nuclear Receptors in Nonalcoholic Fatty Liver Disease
López-Velázquez, J. A., Carrillo-Córdova, L. D., Chávez-Tapia, N. C., Uribe, M., & Méndez-Sánchez, N. (2012) · Journal of Lipids · doi:10.1155/2012/139875 · Cited by 48
Non-alcoholic fatty liver disease: pathogenesis and models
Zhong, H. (2024) · American Journal of Translational Research · doi:10.62347/kmsa5983 · Cited by 37
Lee, S. R., Kwon, S. W., Kaya, P., Lee, Y. H., Lee, J. G., Kim, G., Lee, G.-S., Baek, I.-J., & Hong, E.-J. (2018) · Scientific Reports · doi:10.1038/s41598-018-34148-6 · Cited by 37
Arai, T., Atsukawa, M., Tsubota, A., Ono, H., Kawano, T., Yoshida, Y., Okubo, T., Hayama, K., Nakagawa‐Iwashita, A., Itokawa, N., et al. (2022) · JGH Open · doi:10.1002/jgh3.12780 · Cited by 34
The Human Gut Microbiome in Liver Diseases
Davis, B., & Bajaj, J. (2017) · Seminars in Liver Disease · doi:10.1055/s-0037-1602763 · Cited by 34
Managing diabetes in patients with chronic liver disease
Khan, R., Foster, G. R., & Chowdhury, T. A. (2012) · Postgraduate Medicine · doi:10.3810/pgm.2012.07.2574 · Cited by 34
FDG PET/CT of the non-malignant liver in an increasingly obese world population
Keramida, G., & Peters, A. M. (2020) · Clinical Physiology and Functional Imaging · doi:10.1111/cpf.12651 · Cited by 25
The effect of QuYuHuaTanTongLuo Decoction on the non-alcoholic steatohepatitis
Zhang, S.-J., Chen, Z.-X., Jiang, K.-P., Cheng, Y.-H., & Gu, Y.-L. (2008) · Complementary Therapies in Medicine · doi:10.1016/j.ctim.2007.08.004 · Cited by 25
Effect of FTY720P on lipid accumulation in HEPG2 cells
Rida, R., & Kreydiyyeh, S. (2023) · Scientific Reports · doi:10.1038/s41598-023-46011-4 · Cited by 14
Prevention of NAFLD/NASH by Astaxanthin and β-Cryptoxanthin
Ota, T. (2021) · Advances in Experimental Medicine and Biology · doi:10.1007/978-981-15-7360-6_21 · Cited by 10
The Effect of Laparoscopic Sleeve Gastrectomy on Nonalcoholic Fatty Liver Disease
Batman, B., Altun, H., Simsek, B., Aslan, E., & Namli Koc, S. (2019) · Surgical Laparoscopy, Endoscopy & Percutaneous Techniques · doi:10.1097/sle.0000000000000672 · Cited by 9
Clinicopathologic features of de novo non-alcoholic steatohepatitis in the post-transplant setting
Balitzer, D., Tsai, J.-H., & Gill, R. M. (2022) · Diagnostic Pathology · doi:10.1186/s13000-022-01247-y · Cited by 5
Metadata
- Authors
- Farrell, G. C., & Larter, C. Z.
- Venue
- Hepatology
- Published
- 2006-02
- Volume
- 43
- Issue
- Supplement 1
- Pages
- S99-S112
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2047257800
- Cited by
- 2,414
- References
- 157
- FWCI
- 86.32
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.